GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Kennedy Jr. has his way, get ready for even more anti-pharma rhetoric and potential instability at ... FDA and has called for ...

British pharmaceutical company GSK said on Wednesday that it has agreed ... of the Zantac state court product liability cases pending against GSK," the company said in a statement.

GSK's severe asthma therapy Nucala could ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Bearish flow noted in GSK (GSK) Pharma with 3,674 puts trading, or 5x expected. Most active are 10/25 weekly 38 puts and Nov-24 40 calls, with total volume in those strikes near 3,100 contracts.

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...

Pharmaceutical and agricultural companies are among the industry groups pushing against a proposed levy on their returns from ...